Abstract
Introduction
The reporting of osteonecrosis of the jaw (ONJ) related to anticancer agents without known antiresorptive properties (non-antiresorptives), such as antiangiogenics, tyrosine kinase inhibitors, mammalian target of rapamycin inhibitors, immune checkpoint inhibitors, and cytotoxic chemotherapy is increasing.
Objective
To review characteristics of ONJ in cancer patients receiving non-antiresorptives.
Methods
A systematic review of the literature between 2009 and 2017 was conducted by the Bone Study Group of MASCC/ISOO.
Results
Of 6249 articles reviewed and from personal communication, 42 ONJ cases related to non-antiresorptives were identified. No gender predilection was noted. Median age was 60 years and ONJ stage 2 was most common, with predilection for posterior mandible. Exposed bone, pain, and infection were common at diagnosis. In comparison to bone targeting agents (BTAs), radiology, histology, and management were similar, with medication often discontinued. Delayed diagnosis (median 8 weeks) was noted.
Important differences included earlier time to ONJ onset (median 20 weeks), absence of trigger event (40%), and greater likelihood of healing and shorter healing time (median 8 weeks) as compared to BTA-related ONJ. Gastrointestinal cancers predominated, followed by renal cell carcinomas compared to breast, followed by prostate cancers in BTA-related ONJ, reflecting different medications.
Conclusions
Data about non-antiresorptive-related ONJ is sparse. This type of ONJ may have better prognosis compared to the BTA-related ONJ, suggested by greater likelihood of healing and shorter healing time. However, the delay in diagnosis highlights the need for more education. This is the first attempt to characterize ONJ associated with different non-antiresorptives, including BRAF and immune checkpoint inhibitors.
Similar content being viewed by others
References
Ruggiero SL, Dodson TB, Fantasia J, Goodday R, Aghaloo T, Mehrotra B, O’Ryan F (2014) American Association of Oral Maxillofacial Surgeons position paper on medication-related osteonecrosis of the jaw-2014 update. J Oral Maxillofac Surg 72:1938–1956
Stopek AT, FizaZi K, Body JJ, Brown JE, Carducci M, Diel I et al (2016) Safety of long-term denosumab therapy: results from the open label extension phase of two phase 3 studies in patients with metastatic breast and prostate cancer. Support Care Cancer 24:447–455
Schiodt M, Vadhan-Raj S, Chambers MC, Nicolatou-Galitis O, Politis C, Coropciuc R, Fedele S, Jandial D, Zhang J et al (2018) A multicenter case registry study on medication-related osteonecrosis of the jaw in patients with advanced cancer. Support Care Cancer 26:1905–1915
Van Cann T, Loyson T, Verbiest A, Clement OM, Bechter O, Willems L et al (2018) Incidence of medication-related osteonecrosis of the jaw in patients treated with bone resorption inhibitors and vascular endothelial growth factor receptor tyrosine kinase inhibitors. Support Care Cancer 26:869–878
Fung PPL, Bedogni G, Bedogni A, Petrie A, Porter S, Campisi G, Bagan J, Fusco V, Saia G, Acham S, Musto P, Petrucci MT, Diz P, Colella G, Mignogna MD, Pentenero M, Arduino P, Lodi G, Maiorana C, Manfredi M, Hallberg P, Wadelius M, Takaoka K, Leung YY, Bonacina R, Schiødt M, Lakatos P, Taylor T, de Riu G, Favini G, Rogers SN, Pirmohamed M, Nicoletti P, GENVABO Consortium, Fedele S (2017) Time to onset of bisphosphonate-related osteonecrosis of the jaws: a multicenter retrospective cohort study. Oral Dis 23:477–483
Pilanci KN, Alco G, Ordu C, Sarsenov D, Celebi F, Erdogan Z, Agacayak F, Ilgun S, Tecimer C, Demir G, Erlp Y, Okkan S, Ozmen V (2015) Is administration of trastuzumab an independent risk factor for developing osteonecrosis of the jaw among metastatic breast cancer patients under zoledronic acid treatment? Medicine 94:e671. https://doi.org/10.1097/MD.0000000000000671
Gaudin E, Seidel L, Bacevic M, Rompen E, Lambert F (2015) Occurrence and risk indicators of medication-related osteonecrosis of the jaw after dental extraction: a systematic review and meta-analysis. J Clin Periodontol 42:922–932
McGowan K, McGowan T, Ivanovski S (2017). Risk factors for medication-related osteonecrosis of the jaws: a systematic review. Oral Dis 1-10. doi:https://doi.org/10.1111/odi.12708
Pimolbutr K, Porter S, Fedele S (2018). Osteonecrosis of the jaw associated with antiangiogenics in antiresorptive-naïve patient: a comprehensive review of the literature BioMed Res Int Article ID 8071579, doi: https://doi.org/10.1155/2018/8071579
Fusco V, Santini D, Armento G, Tonini G, Campisi G (2016) Osteonecrosis of the jaw beyond antiresorptive (bone-targeted) agents: new horizons in oncology. Expert Opin Drug Saf 15(7):925–935
Nicolatou-Galitis O, Papadopoulou E, Sarri T, Boziari P, Karayanni A, Kyrtsonis MC. Repousis P, Barbounis V, Migliorati C (2011). Osteonecrosis of the jaw in oncology patients treated with bisphosphonates: prospective experience of a dental oncology referral center. Oral Surg Oral Med Oral Pathol Oral Radiol 112:195–202
Vardas E, Coward T, Papadopoulou E, Nicolatou-Galitis O (2014) Dental extractions as the major local risk factor of bisphosphonates related jaw osteonecrosis in cancer therapy. A systematic review. Mediterranean Oncol J-MOJ 1:26–33
Fedele S, Porter SR, D’Aiuto F, Aljohani S, Vesconi P, Mafredi M, Arduino PG, Broccoletti R, Musciotto A, Di Fede O, Lazarovici TS, Campisi G (2010) Nonexposed variant of bisphosphonate-associated osteonecrosis of the jaw: a case series. Am J Med 123:1060–1064
Bedogni A, Fusco V, Agrillo A, Campisi G (2012) Learning from experience. Proposal of a refined definition and staging system for bisphosphonate-related osteonecrosis of the jaw (BRONJ). Oral Dis 18:621–623
Schiodt M, Reibel J, Oturai P, Kofod T (2014) Comparison of nonexposed and exposed bisphosphonate-induced osteonecrosis of the jaws: a retrospective analysis from the Copenhagen cohort and a proposal for an updated classification system. Oral Surg Oral Med Oral Pathol Oral Radiol 117:204–213
Papadopoulou E, Nicolatou-Galitis O, Razis E, et al (2017). Localized alveolar bone disease prior to dental extraction in cancer patients treated with antiresorptives: an early stage of osteonecrosis of the jaw (ONJ)? [oral presentation]. Presented at the Multinational Association of Supportive Care in Cancer congress, 22–24 June 2017. Washington DC, USA 2017
Troeltzsch M, Woodlock T, Kriegelstein S, Steiner T, Messlinger K, Mar T (2012) Physiology and pharmacology of nonbisphopshonate drugs implicated in osteonecrosis of the jaw. J Can Dent Assoc 78:c85
Bowen JM, Elad S, Hutchins RD, Lalla RV (2013) Methodology for the MASCC/ISOO mucositis clinical practice guideline update. Support Care Cancer 21:303–308
Hadorn DC, Baker D, Hodges JS, Hicks N (1996) Rating the quality of evidence for clinical practice guidelines. J Clin Epidemiol 49:749–754
Somerfield MR, Padberg JJ, Pfister DG, Bennett CL, Recht A, Smith TJ, Weeks JC, Winn RJ, Durant JR (2000) ASCO clinical practice guiedlines: process, progress, pitfalls, and prospects. Classic Pap Curr Comments 4:881–886
Owosho AA, Scordo M, Yom SK, Randazzo J, Chapman PB, Huryn JM, Estilo CL (2015) Osteonecrosis of the jaw a new complication related to ipilimumab. Oral Oncol 51:e100–e101. https://doi.org/10.1016/j.oraloncology.2015.08.014
Mahedi Mohamed HA, Nor Nielsen CE, Schiodt M (2018) Medication related osteonecrosis of the jaws associated with targeted therapy as monotherapy and in combination with anti-resorptives. A report of seven cases from the Copenhagen ONJ cohort. Oral Surg Oral Med Oral Pathol Oral Radiol 125:157–163. https://doi.org/10.1016/j.oooo.2017.10.010
Aghaloo TL, Tetradis S (2017) Osteonecrosis of the jaw in the absence of antiresorptive or antiangiogenic exposure: a series of 6 cases. J Oral Maxillofac Surg 75:129–142
Omarini C, Filieri ME, Depenni R, Grizzi G, Cascinu S, Piacentini F (2017). Osteonecrosis of the jaw in a breast cancer patient treated with everolimus and a single dose of zoledronic acid. The Breast J 1–2. doi: https://doi.org/10.1111/tbj.12808
Viviano M, Rossi M, Cocca S (2017) A rare case of osteonecrosis of the jaw related to imatinib. J Korean Assoc Oral Maxillofac Surg 43:120–124. https://doi.org/10.5125/jkaoms.2017.43.2.120
Erovigni F, Gambino A, Cabras M, Fasciolo A, Bianchi SD, Bellini E, Fusco V (2016) Delayed diagnosis of osteonecrosis of the jaw (ONJ) associated with bevacizumab therapy in colorectal cancer patients: report of two cases. Dent J 4:39. https://doi.org/10.3390/dj4040039
Yamamoto D, Tsubota Y, Utsunomiya T, Sueoka N, Ueda A, Endo K, Yoshikawa K, Kon M (2017) Osteonecrosis of the jaw associated with everolimus: a case report. Mol Clin Oncol 6:255–257. https://doi.org/10.3892/mco.2016.1100
Zarringhalam P, Brizman E, Shakib K (2017) Medication-related osteonecrosis of the jaw associated with aflibercept. Br J Oral Maxillofac Surg 55:314–315. https://doi.org/10.1016/j.bjoms.2016.11.315
Patel V, Sproat C, Kwok J, Tanna N (2017) Axitinib-related osteonecrosis of the jaw. Oral Surg Oral Med Oral Pathol Oral Radiol 124:e257–e260
Antonuzzo L, Lunghi A, Giommoni E, Brugia M, Di Costanzo F (2016) Regorafenib also can cause osteonecrosis of the jaw. J Natl Cancer Inst 108:djw002. https://doi.org/10.1093/jnci/djw002
DeSeza CR, Appugoumder S, Haberland C, Johnson MP (2016) Osteonecrosis of the jaw in association with cutaneous T-cell lymphoma. J Oral Maxillofac Surg 74:292–301
Garuti F, Camelli V, Spinardi L, Bucci L, Trevisani F (2016) Osteonecrosis of the jaw during sorafenib therapy for hepatocellular carcinoma. Tumori 102(Suppl 2):S69–S70. https://doi.org/10.5301/tj.5000504
Mawardi H, Enzinger P, McCleary N, Manon R, Villa A, Treister N, Woo S-B (2016) Osteonecrosis of the jaw associated with ziv-aflibercept. J Gastrointest Oncol 7:e81–e87. https://doi.org/10.21037/jgo.2016.05.07
Melloni C, Tuttolomondo A, Anfosso A, Calamia C, Clemente FD, Cordova A (2016) Sunitinib related osteonecrosis of the jaw (SURONJ): a rare occurrence? Eur J Plast Surg 39:161–162
Nicolatou-Galitis O, Galiti D, Moschogianni M, Sachanas S, Edwards BJ, Migliorati CA, Pangalis G (2016) Osteonecrosis of the jaw in a patient with acute myeloid leukemia, who received azacitidine. J Cancer Metasta Treat 2:220–223
Ponzetti A, Pinta F, Spadi R, Mecca C, Fanchini L, Zanini M, Ciuffreda L, Racca P (2016) Jaw osteonecrosis associated with aflibercept, irinotecan and fluorouracil: attention to oral district. Tumori 102(Suppl 2):S74–S77. https://doi.org/10.5301/tj.5000405
Marino R, Orlandi F, Arecco F, Gandolfo S, Pentenero M (2015) Osteonecrosis of the jaw in a patient receiving cabozantinib. Austr Dental J 60:528–531. https://doi.org/10.1111/adj.12254
Kim DW, Jung Y-S, Park H-S, Jung H-D (2013) Osteonecrosis of the jaw related to everolimus: a case report. Br J Oral Maxillofac Surg 51:e302–e304. https://doi.org/10.1016/j.bjoms.2013.09.008
Nicolatou-Galitis O, Razis E, Galiti D, Vardas E, Tzerbos F, Labropoulos S (2013) Osteonecrosis of the jaw in a patient with chronic myelogenous leukemia receiving imatinib - a case report with clinical implications. Forum Clin Oncol 4:29–33
Pakosch D, Papadimas D, Munding J, Kawa D, Kriwalsky MS (2013) Osteonecrosis of the mandible due to anti-angiogenic agent, bevacizumab. Oral Maxillofac Surg 17:303–306. https://doi.org/10.1007/s10006-012-0379-9
Santos-Silva AR, Rosa GAB, de Castro JG, Dias RB, Ribeiro ACP, Brandão TB (2013) Osteonecrosis of the mandible associated with bevacizumab therapy. Oral Surg Oral Med Oral Pathol Oral Radiol 115:e32–e36
Bettini G, Blandamura S, Saia G, Bedogni A (2012) Bevacizumab-related osteonecrosis of the mandible is a self-limiting disease process. BMJ Case Rep 2012:bcr2012007284. https://doi.org/10.1136/bcr-2012-007284
Brunamonti Binello P, Bandelloni R, Labanca M, Buffoli B, Rezzani R, Rodella LF (2012) Osteonecrosis of the jaws and bevacizumab therapy: a case report. Int J Immunopathol Pharmacol 25:789–791
Disel U (2012) A case report of bevacizumab-related osteonecrosis of the jaw: old problem, new culprit. Oral Oncol 48:e2–e3. https://doi.org/10.1016/j.oraloncology.2011.07.030
Fleissig Y, Regev E, Lehman H (2012) Sunitinib related osteonecrosis of jaw: a case report. Oral Surg Oral Med Oral Pathol Oral Radiol 113:e1–e3
Infante-Cossio P, Lopez-Martin JC, Gonzelez-Gardero E, Martinez-de-Fuentes R, Casas-Fernadez-Tejerina A (2012) Osteonecrosis of the maxilla associated with cancer chemotherapy in patients wearing dentures. J Oral Maxillofac Surg 70:1587–1592
Nicolatou-Galitis O, Migkou M, Psyrri A, Bamias A, Pectasides D, Economopoulos T, Raber-Durlacher JE, Dimitriadis G, Dimopoulos MA (2012) Gingival bleeding and jaw bone necrosis in patients with metastatic renal cell carcinoma receiving sunitinib: report of 2 cases with clinical implications. Oral Surg Oral Med Oral Pathol Oral Radiol 113:234–238. https://doi.org/10.1016/j.tripleo.2011.08.024
Koch FP, Walter C, Hansen T, Jäger E, Wagneret W (2011) Osteonecrosis of the jaw related to sunitinib. Oral Maxillofac Surg 15:63–66. https://doi.org/10.1007/s10006-010-0224-y
Serra E, Paolantonio M, Spoto G, Mastrangelo F, Tete S, Dolci M (2009) Bevacizumab-related osteneocrosis of the jaw. Int J Immunopathol Pharmacol 22(4):1121–1123
Estilo CL, Fornier M, Farooki A, Carlson D, Bohle G III, Huryn JM (2008) Osteonecrosis of the jaw related to bevacizumab. JCO 26:4037–4038
Greuter S, Schmid F, Ruhstaller T, Thuerlimann B (2008) Bevacizumab-associated osteonecrosis of the jaw. Ann Oncol 19:2091–2092
Hallmer F, Bjornland T, Nicklasson A, Becktor JP, Andersson G (2014) Osteonecrosis of the jaw in patients treated with oral and intravenous bisphosphonates: experience in Sweden. Oral Surg Oral Med Oral Pathol Oral Radiol 118:202–208
Fortuna G, Ruoppo E, Pollio A, Aria M, Adamo D, Leuci S, Dell’Aversana Orabona G, Mignogna MD (2012) Multiple myeloma vs. breast cancer patients with bisphopshonates-related osteonecrosis of the jaws: a comparative analysis of response to treatment and predictors of outcome. J Oral Pathol Med 41:222–228
Ramaglia L, Guida A, Iorio-Siciliano V, Cuozzo A, Blasi A, Sculean A (2018). Stage-specific therapies of medication-related osteonecrosis of the jaws: a systematic review and meta-analysis of the drug suspension protocol. Clin Oral Invest 597-615, doi: https://doi.org/10.1007/s00784-017-2325-6
Hinson AM, Smith CW, Siegel ER, Stack BC Jr (2014). Is bisphosphonate-related osteonecrosis of the jaw an infection? A histological and microbiological ten-year summary. Internat J Dent article ID 452737, https://doi.org/10.1155/2014/452737
Nicolatou-Galitis O, Razis E, Galiti D, Galitis E, Labropoulos S, Tsimpidakis A, Sgouros J, Karampeazis A, Migliorati C (2015) Periodontal disease preceding osteonecrosis of the jaw (ONJ) in cancer patients receiving antiresorptives alone or combined with targeted therapies: report of 5 cases and literature review. Oral Surg Oral Med Oral Pathol Oral Radiol 120:699–706
Otto S, Pautke C, Jurado OM< Nehrbass D, Stoddart MJ, Ehrenfeld M, Zeiter S (2017). Further development of the MRONJ minipig large animal model. J Cranio-maxillo-Facial Surg 45:1503–1514
Coropciuc RG, Grisar K, Aerden T, Schol M, Schoenaers J, Politis C (2017) Medication-related osteonecrosis of the jaw in oncological patients with skeletal metastases: conservative treatment is effective up to stage 2. Br J Oral Maxillofac Surg 55:787–792
Oken MM, Creech RH, Tormey DC, Horton J (1982) Toxicity and response criteria of the eastern cooperative oncology group. Am J Clin Oncol 5:649–655
Tanna N, Steel C, Stagnell S, Bailey E (2017) Awareness of medication related osteonecrosis of the jaws (MRONJ) amongst general dental practitioners. Br Dental J 222:121–125
Kim JW, Jeong SR, Kim SJ, Kim YS (2016) Perceptions of medical doctors on bisphosphonate-related osteonecrosis of the jaw. BMC Oral Health 16:92. https://doi.org/10.1186/s12903-016-0290-0
Taguchi A, Shiraki M, Sugimoto T, Ohta H, Soen S, Japan Osteoporosis S (2016) Lack of cooperation between physicians and dentists during osteoporosis treatment may increase fractures and osteonecrosis of the jaw. Curr Med Res Opin 32:1261–1268
Nicolatou-Galitis O, Migliorati C. (2018) Osteonecrosis of the jaw (ONJ) in patients who receive bone targeting agents (BTAs): the power of e-learning. ecancermedicalscience. 12
Acknowledgements
We thank the MASCC Board for the opportunity to work on this project, within the Bone Study Group.
Author information
Authors and Affiliations
Consortia
Corresponding author
Ethics declarations
Conflict of interest
Ourania Nicolatou-Galitis and Cesar Migliorati have received consultant fee from AMGEN. Maria Kouri, Erofili Papadopoulou, Emmanouil Vardas, Dimitra Galiti, Joel Epstein, Sharon Elad, Giuseppina Campisi, Nikolaos Tsoukalas, Kivanc Bektas-Kayhan, Winston Tan, Jean-Jacques Body, and Rajesh Lalla declare no conflict of interest.
Rights and permissions
About this article
Cite this article
Nicolatou-Galitis, O., Kouri, M., Papadopoulou, E. et al. Osteonecrosis of the jaw related to non-antiresorptive medications: a systematic review. Support Care Cancer 27, 383–394 (2019). https://doi.org/10.1007/s00520-018-4501-x
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00520-018-4501-x